New oral antiplatelet agent ticagrelor approved in Korea

Published: 2011-07-27 06:59:00

Updated: 2011-07-27 06:59:00

The Korea Food and Drug Administration said Thursday that it has approved AstraZeneca’s Brilinta (ticagrelor) to reduce the rate of heart attack (myocardial infarction; MI) and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS).

Ticagrelor, a new oral antiplatelet m...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK